Rhiza Labs FluTracker Forum

Clinically and epidemiologically relevant resistance (>50% of viral quasi-species in the original clinical material harbour the H275Y mutation) are reported weekly in HPA weekly influenza reports, to the European Centre for Disease Prevention and Control (ECDC) via the European Surveillance System (TESSy) and to the World Health Organization (WHO) headquarters and the WHO Regional Office for Europe. Clinical specimens with quasi-species harbouring <50% resistant virus are reported back to clinicians as resistant for patient management but not internationally, according to the agreed WHO strategy (Technical consultation meeting (8 September 2010) proceedings paper under preparation by the WHO).

http://www.eurosurveillance.org/ViewArt ... leId=19784

_________________
www.twitter.com/hniman

As acknowledged above, samples which had H274Y at levels below 50% are NOT reported to the general public. These cases are reported to clinicians because these high levels of H274Y will quickly rise to 100% as soon as Tamiflu treatment is started.

In the above comments this scam is acknowledged, which is explains why resistance appears so rapidly after the start of treatment.

Once again science is hijacked for political propaganda designed to minimize the true level of Tamiflu resistance in pandemic H1N1.

Influenza is ALL about politics, no science required.

_________________
www.twitter.com/hniman

I suspect some cases in Mexico are showing resistance to Oseltamivir. It wouldn't be a big surprise as H274Y is spreading in the community.

The cluster in Delaware was a clear sign that H274Y is transmitting. The level is much higher than representations in the "concensus" sequences because levels like 5-30% just disappear (but go to 100% as soon as Tamiflu treatment begins).

_________________
www.twitter.com/hniman

Scam aiding and abetting by HPA:

Only cases with >50% resistant viruses in the sample will be designated resistant and reported publicly, nationally and internationally, by the HPA.

Presumptive (screening) diagnosis of oseltamivir resistance will be reported within HPA and the devolved administrations, but not disseminated further. This will enable the reference laboratory to be aware of all viruses they should be testing for confirmation. Such data will not be used to form the numerator of resistant cases nationally. Treatment outcome in cases with low proportions of resistant virus (<50% H275Y viruses in the sample) may be affected and will be reported to the clinician involved, but will not be reported nationally, in accordance with suggested protocols for reporting to WHO (WHO technical discussion Hong Kong 2010).

http://www.hpa.org.uk/web/HPAwebFile/HP ... 7147818576

_________________
www.twitter.com/hniman

Commentary

http://www.recombinomics.com/News/03301 ... _Scam.html

_________________
www.twitter.com/hniman